Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00708006 · ClinicalTrials.gov registry record · Phase 1
A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Human Genome Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
- 3
- Study locations
NCT00708006: Completed Phase 1 study of Advanced Solid Tumors, sponsored by Human Genome Sciences.
NCT00708006 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Human Genome Sciences. The registered enrollment target is 66 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (67% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00708006, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Human Genome Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.
Conditions Studied
Interventions
- DRUG HGS1029
Study Locations (3)
California
- Stanford University Dept. of Medicine-Oncology - Stanford
Colorado
- University of Colorado Health Sciences Center - Aurora
Tennessee
- The Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
What the finished NCT00708006 record still lists
NCT00708006 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which HGS1029 is the first listed.
NCT00708006 reports a single indexed study location in California, Colorado, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00708006 about?
NCT00708006 is a clinical study titled "A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors". The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.
What is the current status of trial NCT00708006?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2008-05. Estimated completion is 2012-01.
What conditions does trial NCT00708006 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT00708006?
The interventions under investigation include: HGS1029 (DRUG).
Who is sponsoring clinical trial NCT00708006?
This trial is sponsored by Human Genome Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00708006 being conducted?
This trial has 3 study locations across California, Colorado, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00708006's enrollment target sits among peer trials
66 94th of 144 higher than 50 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia